Exscientia plc (NASDAQ:EXAI) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its holdings in Exscientia plc (NASDAQ:EXAI) by 2.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,574,405 shares of the company’s stock after selling 116,075 shares during the period. Baillie Gifford & Co. owned 3.78% of Exscientia worth $26,166,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Exscientia by 112.1% in the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after buying an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Exscientia by 359.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after purchasing an additional 4,104 shares during the period. Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Exscientia in the fourth quarter valued at about $64,000. Colonial River Wealth Management LLC purchased a new stake in shares of Exscientia in the fourth quarter valued at about $86,000. Finally, New Republic Capital LLC purchased a new stake in shares of Exscientia in the fourth quarter valued at about $128,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Stock Performance

Shares of EXAI traded up $0.38 during mid-day trading on Friday, hitting $5.75. 485,039 shares of the company’s stock were exchanged, compared to its average volume of 430,319. Exscientia plc has a fifty-two week low of $3.86 and a fifty-two week high of $9.12. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.05. The stock’s 50-day moving average is $5.11 and its 200-day moving average is $5.63.

Exscientia (NASDAQ:EXAI) last issued its quarterly earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $6.70 million for the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. On average, analysts forecast that Exscientia plc will post -1.07 EPS for the current fiscal year.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.